These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 15592581)

  • 21. Aripiprazole: profile on efficacy and safety.
    Goodnick PJ; Jerry JM
    Expert Opin Pharmacother; 2002 Dec; 3(12):1773-81. PubMed ID: 12472374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability.
    DeLeon A; Patel NC; Crismon ML
    Clin Ther; 2004 May; 26(5):649-66. PubMed ID: 15220010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism.
    Naber D; Lambert M
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Dec; 28(8):1213-9. PubMed ID: 15588748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.
    Shapiro DA; Renock S; Arrington E; Chiodo LA; Liu LX; Sibley DR; Roth BL; Mailman R
    Neuropsychopharmacology; 2003 Aug; 28(8):1400-11. PubMed ID: 12784105
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aripiprazole in the treatment of schizophrenia: a consensus report produced by schizophrenia experts in Italy.
    Cassano GB; Fagiolini A; Lattanzi L; Monteleone P; Niolu C; Sacchetti E; Siracusano A; Vita A
    Clin Drug Investig; 2007; 27(1):1-13. PubMed ID: 17177576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aripiprazole: does partial dopaminergic agonism translate into clinical benefits?
    Crismon ML; DeLeon A; Miller AL
    Ann Pharmacother; 2003 May; 37(5):738-40. PubMed ID: 12708954
    [No Abstract]   [Full Text] [Related]  

  • 27. Aripiprazole acts as a selective dopamine D2 receptor partial agonist.
    Wood M; Reavill C
    Expert Opin Investig Drugs; 2007 Jun; 16(6):771-5. PubMed ID: 17501690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intramuscular aripiprazole : a review of its use in the management of agitation in schizophrenia and bipolar I disorder.
    Sanford M; Scott LJ
    CNS Drugs; 2008; 22(4):335-52. PubMed ID: 18336061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aripiprazole: pharmacology and evidence in bipolar disorder.
    McIntyre RS; Soczynska JK; Woldeyohannes HO; Miranda A; Konarski JZ
    Expert Opin Pharmacother; 2007 May; 8(7):1001-9. PubMed ID: 17472545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aripiprazole: a review of its pharmacology and clinical use.
    Taylor DM
    Int J Clin Pract; 2003; 57(1):49-54. PubMed ID: 12587943
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biological perspectives. Aripiprazole: a third generation of antipsychotics begins?
    Keltner NL; Johnson V
    Perspect Psychiatr Care; 2002; 38(4):157-9. PubMed ID: 12629954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
    Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanism of new antipsychotic medications: occupancy is not just antagonism.
    Grunder G; Carlsson A; Wong DF
    Arch Gen Psychiatry; 2003 Oct; 60(10):974-7. PubMed ID: 14557141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of antipsychotic-induced hyperprolactinemia: an update on the role of the dopaminergic receptors D2 partial agonist aripiprazole.
    De Berardis D; Fornaro M; Serroni N; Marini S; Piersanti M; Cavuto M; Valchera A; Mazza M; Girinelli G; Iasevoli F; Perna G; Martinotti G; Di Giannantonio M
    Recent Pat Endocr Metab Immune Drug Discov; 2014 Jan; 8(1):30-7. PubMed ID: 24372345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical impact of aripiprazole in patients suffering from schizophrenia].
    Levoyer D; Drapier D; Fadier-Salicé G; Millet B
    Encephale; 2007; 33(3 Pt 1):332-8. PubMed ID: 17675931
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aripiprazole (Otsuka Pharmaceutical Co).
    Ozdemir V; Fourie J; Ozdener F
    Curr Opin Investig Drugs; 2002 Jan; 3(1):113-20. PubMed ID: 12054061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quinoline- and isoquinoline-sulfonamide analogs of aripiprazole: novel antipsychotic agents?
    Zajdel P; Partyka A; Marciniec K; Bojarski AJ; Pawlowski M; Wesolowska A
    Future Med Chem; 2014 Jan; 6(1):57-75. PubMed ID: 24358948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Worsened agitation with aripiprazole: adverse effect of dopamine partial agonism?
    DeQuardo JR
    J Clin Psychiatry; 2004 Jan; 65(1):132-3. PubMed ID: 14976671
    [No Abstract]   [Full Text] [Related]  

  • 39. Medications for stimulant abuse: agonist-based strategies and preclinical evaluation of the mixed-action D-sub-2 partial agonist aripiprazole (Abilify).
    Bergman J
    Exp Clin Psychopharmacol; 2008 Dec; 16(6):475-83. PubMed ID: 19086768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity.
    Tuplin EW; Holahan MR
    Curr Neuropharmacol; 2017 Nov; 15(8):1192-1207. PubMed ID: 28412910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.